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Summary 
Interleukin 10 (I1.10) is a pleiotropic factor that enhances proliferation of activated  human B 
lymphocytes and induces them to secrete high amounts of immunoglobulins. Here we show 
that several human B cell lines were able to constitutively secrete human (h)Ibl0. Whereas none 
of the pre-B nor the plasmocytic cell lines tested produced hi1-10, 25 of the 36 tested mature 
B cell lines (lymphoblastoid and Burkitt lymphoma cell lines) secreted hi1.10. Moreover,  24 of 
these 25 hI1-10-producing B cell lines contained the Epstein-Barr virus (EBV) genome, suggesting 
a relationship between hi1.10 production by human B cell lines and EBV expression. Accordingly, 
whereas polyclonal activation via triggering of surface immunoglobulins  or CD40 antigen induced 
highly purified normal human B lymphocytes to produce only low (0.3-0.4 ng/ml) but significant 
amounts of hIbl0, EBV infection induced them to secrete high amounts of hi1.10 (4-9 ng/ml). 
Furthermore, addition of exogenous hIbl0, simultaneously to EBV infection, potentiated cell 
proliferation, whereas a blocking anti-Ibl0 antiserum inhibited it. Thus, hi1.10 produced by 
infected human B lymphocytes appears to be involved in the mechanisms of EBV-induced B cell 
proliferation. 
T 
o produce specific antibodies in response to antigenic 
stimulations (1), B lymphocytes interact with other im- 
munocompetent cells. B cells are able to efficiently present 
antigen to T cells in an MHC-restricted context (2), and also 
to produce soluble immunomodulatory mediators. Indeed, 
both normal and malignant B lymphocytes have the ability 
to secrete cytokines. The constitutive or induced secretion 
of I1.1 (3), I1.6 (4), TNF (5, 6) and soluble CD23 (7) has 
already been reported. B lymphomas, myelomas, and EBV- 
infected B cell lines have been described to produce I1.1 (8), 
I1.5 (9), I1.6 (10), or TNF-oe and -~ (5, 6), with some of 
these cytokines suspected to act as autocrine growth factors 
(11-13). 
I1-10 has been initially identified: (a) as a cytokine syn- 
thesis inhibitory factor, produced by Th2 cell clones, inhibiting 
macrophage-APC-dependent cytokine synthesis by Thl cell 
clones (14); and (b)  as a Lyl + B  cell lymphoma product 
potentiating IL-2- or I1-4-dependent proliferation of thymo- 
cytes  (15, 16). Human  I1.10  (hlL-10)  1 and  murine  I1.10 
(mI1.10) genes display >80% of homology (17, 18). Further- 
more, hi1.10 exhibits a strong DNA and amino acid sequence 
homology to an open reading frame of the EBV genome: 
BCRF1 or viral I1.10 (vii.10) (18). vii.10 is expressed during 
1 Abbreviations used in th/s  ~per: CSIE cytokine synthesis inhibitory factor; 
h,  human; m, murine; SAC, Staphylococcus aureus Cowan I; v, viral. 
the late stage of the virus cycle and exhibits most of the ac- 
tivities of h and mlbl0 (17-20).  In the murine system, Ib 
10, just like I1.4, enhances MHC class II expression on resting 
B lymphocytes and sustains B cell viability in culture (21). 
In humans, II.-10  potentiates DNA replication orb cells stimu- 
lated via crosslinking of surface CD40 antigen or via surface 
Ig molecules (19). Moreover, 11-10 is a very potent differenti- 
ation factor and induces B cells to secrete high amounts of 
IgM, G,  and A  (19, 20). 
The production of II-10 by normal routine B cells has al- 
ready been characterized  at the mRNA level by PCR and 
at the protein level by ELISA (22). Moreover,  as II:10 is an 
efficient proliferation and differentiation factor for human B 
cells, the present study was initiated to determine whether 
human B lymphocytes were able to secrete this cytokine after 
polyclonal activation. 
Materials and Methods 
Reagents.  Lymphoid B cell lines were cultured in KPMI 1640 
(Gibco Laboratories, Grand Island, NY) supplemented with 10% 
heat-inactivated  FCS (MultiSer, Castel  Hill, New South Wales, Aus- 
tralia), 2 mM glutamin (Gibco Laboratories), and 80/zg/ml ofgen- 
tamycin (gentalline;  Schering-Plough,  Levallois-Perret,  France). Cul- 
tures of normal B lymphocytes  were carded out in modified  Iscove's 
medium as detailed previously (23). Anti-Ibl0 rat mAbs 12G8, 
6Bll, and 9D7 were kindly provided by Dr. J. Abrams (DNAX, 
Palo Alto, CA) (24) and used as purified  products. The neutralizing 
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Briefly, five subcutaneous and intramuscular injections of CHO- 
derived highly purified hlir  (100/~g to I mg of the soluble pro- 
tein), in combination with CFA for the first injection and then 
IFA,  were performed, every month, on female "Fauve de Bour- 
gogne" rabbits.  I wk after the fifth injection, blood was collected, 
and the antisera were isolated.  The antisera  were used at a 1:100 
dilution (see below). The corresponding control was the preim- 
mune serum of the same rabbits before hlL-10 was injected. The 
murine anti-CD40 mAb 89 (25) and anti-IFN-3, mAbs A35 and 
B27  (26) have been produced in our laboratory. 
Insolubilized goat anti-human IgM antibody and formalinized 
particles of Staphylococcus aureus Cowan I (SAC) (Pansorbin)  were 
purchased from Bio-Rad Laboratories (Richmond, CA) and from 
Calbiochem-Behring Corp. (La Jolla, CA), respectively. PMA and 
ionomycin were obtained from Calbiochem-Behring Corp., and 
PHA from Wellcome Laboratories (Paris, France). Cell phenotype 
was determined using FITC-conjugated mAbs originating from 
Becton Dickinson & Co. (Mountain View, CA) or Coulter Immu- 
nology (Hialeah, FL). 
Purified rib2 (5  x  104 U/mg) was  from Amgen Biologicals 
(Thousand  Oaks,  CA).  The  purified  rib4  (107 U/rag;  batch 
8ILE1002) and hIbl0 (10  6 U/mg; batch 27785-82) were obtained, 
respectively, as Escherichia coli and CHO cell products from Schering- 
Plough Research Institute (Bloomfield, NJ). For the early experi- 
ments,  the  hIbl0  was  produced  in  the  laboratory  using  a 
baculovirus/insect  cell system with" a recombinant Autographa califor- 
nica nuclear polyhedrosis virus genome containing the hill0 cDNA, 
kindly provided by Dr. K. W. Moore (DNAX). hIbl0 was used 
as Spodoptera frugipercla Sf9 cell supernatants after its infection by 
recombinant baculovirus.  The yield was from 2 to 5 mg hIbl0 
per liter of culture and was exactly calibrated  against  the purified 
rhIL-10. The vlL-10 used as standard in the vlbl0 ELISA was pro- 
duced in the laboratory by Cos7 cells transfection with the vlL-10 
cDNA-pF115 vector construct, also provided by Dr. K. W. Moore 
(DNAX). The Cos7 vIL-10 was calibrated against purified E. coli- 
derived recombinant vlbl0 (5  x  10  s U/rag) provided by Dr. Ik. 
Kastdein (DNAX). In both cases, the mock control was performed 
using the empty vector. 
Cell Lines.  The  CDw32/Fc3,RII-transfected  Ltk-  cell  line 
(CDw32 L calls) was described earlier (27). The Burkitt lymphoma 
BL, IARC 318, and IARC 518 cell lines were obtained from Dr. 
G. Lenoir (International Agency of Research on Cancer, Lyon, 
France).  The majority of the lymphoblastoid cell lines has been 
obtained in our laboratory. The pre-B cell line pre-Alp was gener- 
ated in the laboratory by Dr. D. Pandrau (manuscript in prepara- 
tion). The chronic lymphocytic leukemia B cells were obtained from 
pathological samples, as described elsewhere (28). The other cell 
lines were from American Type Culture Collection (Rockville, MD). 
Cell Preparations and Cell Cultures.  B cells were isolated  from 
tonsils, peripheral blood, spleen, and cord blood as previously de- 
scribed  (29).  The isolated  population expressed  >98%  CD19 or 
CD20 (B cells), <1% CD2 (T cells), and <1% CD14 (monocytes). 
Isolation of slgD § and slgD-  B cell populations was performed 
using a magnetic activated cell sorter as previously described (20). 
CD5 + B lymphocytes were isolated by cell sorting on a FACStar 
Plus  |  (Becton Dickinson &  Co.).  When  stimulated with SAC 
(0.05%), anti-/~ (10/~g/ml), or PMA (1 ng/ml)  +  ionomycine (5 
/~g/ml),  B  cells  were cultured  at  1@  cells/ml  in  96-well  flat- 
bottomed microtiter plates (Falcon Labware, Oxnard, CA). In the 
CD40 system (30,  31), purified B lymphocytes were cultured at 
0.2-1  x  106 cells/ml with irradiated (7,500 rad) CDw32 L cells 
at 0.25-1  ￿  10  s cells/ml and with 0.5/zg/ml of anti-CD40 mAb 
89. 11,4 (100 U/ml), IL-2 (20 U/ml), and IL-10 (100 ng/ml) were 
added when appropriate.  For EBV infection of purified B lympho- 
cytes, 50/~1 ofa 100x concentrated culture supernatant of the B95.8 
viral strain  was added on B cells at 10Vml in RPMI.  After 2 h 
of incubation at 37~  cells were washed and cultured at 5  x  10  s 
cells/ml. For each condition, cultures were performed in triplicates. 
Supernatants of these cultures were harvested at different time points 
and tested in the II.-10 ELISAs. 
Cytokine Synthesis Inhibitory Factor  (CSIF) Assay.  The rabbit poly- 
clonal anti-Ibl0 antisera were tested for their ability to neutralize 
the activity of purified hlL.10 in CSIF assays, performed as previ- 
ously described (14). Briefly, spleen mononuclear cells were acti- 
vated in 96-well flat-bottomed microtiter plates (Falcon Labware), 
by a combination of SAC (0.05%), PHA (5/zg/ml), and Ib2 (100 
U/ml) in the presence  of serial concentrations of purified hlL-10 
(0.1-100 ng/ml), with or without addition of anti-IL-10 or control 
antisera  (diluted at 1:100, 1:1,000 or 1:10,000). The neutralizing 
effect of the anti-IL-10 antiserum on the inhibition of IFN-3, produc- 
tion induced by hlL-10 was determined after 72 h of culture using 
an IFN-3' ELISA as previously described  (26). 
11_,I0 ELISAs.  Both II.-10 ELISAs are developed on the pat- 
tern of a two-site sandwich ELISA format as previously described 
(26). One assay quantitates both h and vlbl0 while the other one 
is specific of vlbl0.  Both assays rely on the same catcher mAb, 
9D7, and the specificity is determined by the tracer biotinylated 
antibody: mAb 12G8 for the h  +  vlL-10 ELISA, and mAb 6Bll 
for the vlL-10 ELISA. Technically, the rat anti-II.,10 mAb, 9D7, 
was coated at 5/~g/ml for 2 h at 37~  under 100/~1, in 96-well 
flat-bottomed microtiter plates (Nunc Immunoplate,  Roskilde, Den- 
mark). After 3 h of saturation with BSA, superuatants were in- 
cubated 2 h at room temperature.  The standards consisted of CHO- 
derived purified hlL-10, with the concentration determined by amino 
acid analysis and Cos7-derived vlL-10, calibrated  against  purified 
rvlbl0. The tracer biotinylated mAbs were then incubated 2 h at 
room temperature: mAb 12G8 (v/hlL-10) was added at 0.05/~g/ml, 
and mAb 6Bll (vlL-10) was added at 0.1/xg/ml. The binding of 
the biotinylated antibodies was revealed with the alkaline phospha- 
tase-conjugated streptavidin (Tago Inc., Burlingame, CA)/phos- 
phatase substrate (Sigma Chemical Co., St. Louis, MO) system as 
previously described (26). The omission or the substitution with 
a nonrelated biotinylated mAb of any one of the mAbs completely 
switched off the signal. Furthermore, 10/~g/ml of hlIr  did not 
react in the vlL-10 ELISA and the vlL-10 similarly reacted in both 
IL-10 ELISAs. The lower detection levels were 100 and 50 pg/ml 
for the h/vlL-10 and the vlL-10, respectively. 
Results 
Human  B  Cell Lines Constitutively Produce  hlL, lO.  More 
than 40 malignant or EBV-transformed B cell lines were tested 
for their ability to produce I1-10. The results obtained for 
this  screening  are  summarized  in  Table  1.  21  malignant 
cell lines were tested first. None of the five pro-B or pre-B 
cell lines produced I1-10. Among the 13 Burkitt lymphoma cell 
lines, representative of the different B cell maturation stages, 
five secreted hi1-10. With the exception of BJAB, all of these 
hI1-10-producing cell lines were EBV positive. However, four 
EBV-positive  Burkitt  lymphoma  cell  lines  (BL29,  BL60, 
BL110, and Daudi) failed to secrete hlbl0.  The preplasmo- 
cytic cell line IAKC 518, obtained from a patient suffering 
from a heavy chain disease, produced 1.7 ng/ml of hi1-10. 
Both plasmocytic cell lines U266 and RPMI  8866 did not 
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Origin  B cell lines  EBV  hlL-10  vlL-10 
ng/ml 
Pro-B  Keh  6  -  <0.1  <0.05 
Pre-B  Nalm  6,  Pre-Alp,  697,  IAKC 318  -  <0.1  <0.05 
Burkitt  lymphoma  BL2,  BL41,  BL45,  BL70  -  <0.1  <0.05 
BJAB  -  10.5  +  3.5  <0.05 
BL29, BL60,  BL110,  Daudi  +  <0.1  <0.05 
BL16  +  3.1  _+  0.5  <0.05 
BL18  +  1.3  _+  0.2  <0.05 
BL74  +  0.9  _+  0.3  <0.05 
Jijoye  +  6.8  _+  2  <0.05 
Lymphoblastoid  IMg,  R.PMI8866,  UD195  +  <0.1  <0.05 
16  different lymphoblastoid cell lines  +  0.3-11  <0.05 
UD189  +  11.2  _+  3  0.2  +  0.05 
UD194  +  3.7  _+  1.3  0.2  _+  0.1 
L38  +  3  •  1.2  0.2  _+  0.04 
Cll  +  5  •  1  0.3  -+  0.1 
Heavy chain  disease  IAKC 518  -  1.7  •  0.5  <0.05 
Myelorna  U266,  KPMI  8226  -  <0.1  <0.05 
The cell line supernatants  were harvested  after 48-96 h of culture and then tested in the IL-10 ELISAs. For each B cell line,  IL-10 concentrations 
are expressed  as mean  _+  SD of two to five independent  assays. 
secrete hlL-10. 23 lymphoblastoid B cell lines, established from 
peripheral blood of normal donors,  were then screened.  20 
of them  secreted 0.3-11  ng/ml  of hlL-10. 
Therefore,  mature human  B cell lines were able to pro- 
duce hiD10,  and this secretion appeared to be at least par- 
tially correlated with EBV expression since 24 of the 26 hilt 
10-secreting cells were EBV positive. Besides, it  should be 
stressed that  only low levels of vlL-10 could be detected in 
the supernatants of a restricted number of EBV-infected cell 
lines. 
The kinetic of hlL-10 secretion by a human B cell line was 
then investigated using the EBV-positive Burkitt lymphoma 
cell  line Jijoye.  B  cells  were  initially  seeded  at  5  x  104 
cells/ml,  and the viable cell recovery was determined daily 
over a 96-h  kinetic.  The corresponding  supernatants  were 
harvested and assayed in the I1.,10 ELISAs. As illustrated in 
Fig. 1, the hiD10 levels detected in the supernatants increased 
together  with  cell concentration:  from 0.2 ng/ml  for  10  s 
cells/ml  after 24 h  of culture,  to 8.1  ng/ml  for 1.4  x  106 
cells/ml after 96 h of culture. The hlL-10 levels did not change 
even when cultures were left unsplit for several more days, 
resulting in a strong cell death. Thus, the highest hlir  con- 
centrations  were  found  in  the  highest  density Jijoye cell 
cultures. 
Normal Human B Lymphocytes  Secrete Low Levels of hlLlO 
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upon Polyclonal Activation.  To determine  whether  normal 
human  B cells could also produce IL-10, highly purified B 
cells and total mononuclear cells, as control, were stimulated 
either with polyclonal activators such as PMA plus ionomy- 
cine,  SAC, or anti-IgM,  or in the CD40 system. Addition 
of IL-2 or II~4 and combinations of two different activation 
I0 7  I0 
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Figure 1.  Kinetic of hlbl0 production by a lymphoid cell line. The 
EBV-positive Burkitt lymphoma cell line Jijoye was cultured at the initial 
cell concentration  of 5  x  104 cells/ml. Viable cell recovery (D) was de- 
termined by trypan blue dye exclusion, and supernatants  were assayed in 
the II.-10 ELISA (O) every 24 h on a 96-h  kinetic. Table  2.  IL-IO  Production by Tonsillar Normal Human Lymphoid Cells 
Cells  Activator  hIL-10  vlL-10  Time 
ng/ml  ng/ml  h 
Mononuclear cells 
(10" cells/ml)  None*  <0.1  <0.05  - 
SAC  +  PHA  +  IL-2*  4.02  _+  0.07  <0.05  72 
Purified B cells 
(10' cells/m1) 
Purified B  cells 
(2  x  1@ cells/ml) 
None*  <0.1  <0.05  - 
PMA  +  ionomycine*  0.36  _+  0,1  <0.05  72 
SAC*  0.34  _+  0.06  <0.05  48 
SAC  +  IL-2*  0,30  _+  0.03  <0.05  48 
Anti-g*  0.36  _+  0.05  <0.05  48 
Anti-/z  +  IL-2*  0.35  _+  0.09  <0.05  48 
CD40*  0.39  +_  0.02  <0.05  24 
CD40  +  IL-4*  0.34  _+  0.07  <0.05  24 
CD40  +  IL-2*  0.40  _+  0.09  <0.05  48 
CD40  +  SAC*  0.32  _+  0.08  <0.05  24 
CD40  +  SAC  +  IL-2*  0.37  +  0.06  <0.05  48 
CD40  +  anti-/z*  0.38  _+  0.1  <0.05  48 
CD40  +  anti-/z  +  IL-2*  0.34  _+  0.05  <0.05  48 
None*  <0.1  <0.05  - 
CD40  +  SAC*  0.74  _+  0.05  <0.05  24 
Mononuclear cells or purified B cells were cultured at 106 or 2  x  106 cells/ml.  SAC was used at 0.05%, anti-# at 10 #g/ml, PMA at 1 ng/ml, 
ionomycine at 5 #g/ml, PHA at 5 #g/ml, IL-4 at 100 U/ml, and IL-2 at 20 U/ml. For the CD40  system reported as CD40,  mAb 89 was used 
at 0.5 #g/ml, and CDw32-transfected L cells  at 0.5  ￿  10  s cells/ml. For a given culture condition, the values of IL-10 production shown represent 
the highest level detected during a 10-d kinetic. The time of culture for which this level was obtained, reproducible for a given culture condition, 
is also mentioned in each case. Results are expressed as mean  _+  SD of independent experiments, all done in triplicates cultures. 
* Four experiments. 
* Two experiments. 
procedures have also been tested. The e~ciency of the activa- 
tion was checked by [3H]thymidine uptake or by Ig produc- 
tion measurements. B cell culture supernatants were harvested 
at different time points: from 4  h  to  10 d,  and then  tested 
in the h/v and vi1,10 ELISAs. The results illustrated in Table 
2 were pooled from several independent experiments performed 
with tonsillar purified B lymphocytes cultured under the same 
conditions. Nonactivated B cells did not produce II,10. Upon 
activation, purified B cells secreted low (compared with acti- 
vated total mononuclear cells) but significant and reproduc- 
ible levels of hlL-10, but no vlbl0. For each activation mode, 
the hi1,10 concentration increased up to 0.3-0.4 ng/ml after 
24-72 h and then progressively decreased down to the detec- 
tion limit level during the next 2-3 d  (see a typical kinetic 
in  Fig.  2).  As shown  in Table 2,  doubling the number  of 
B  cells at culture onset resulted in the secretion of twice as 
much hi1,10.  The activation of total tonsiUar mononuclear 
cells in the CD40 system, with or without II.,4, did not lead 
Figure 2.  hlL-10 production by CD5-enriched human B cells. CD5- 
enriched B cells (<1.5%  CD2*, <4% CD14 +, >80% CD5 +) isolated 
from cord blood were cultured in 106 cells/ml in medium alone (D), with 
SAC +  Ib2 (t~), or in the CD40 system +  SAC (I). In each case, the 
production of hlL-10 on a 96-h kinetic was assayed  by IL-10  ELISAs.  No 
production of vIL-10 was detected. Results are expressed as mean _+  SD 
of triplicate cultures. 
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that, upon these B-specific activation procedures, the weak 
percentage of contaminant non-B cells could not be respon- 
sible for the hlbl0 levels observed in Table 2. Similar levels 
and kinetics of hlL-10 production were also obtained  with 
human B cells isolated from spleen and peripheral blood (data 
not shown). 
We then investigated whether hlbl0 production was re- 
stricted to a subpopulation  of normal human B cells. First, 
supernatants  of activated IgD + and IgD-  B lymphocytes 
contained levels of hlL-10 comparable to those of the unsepa- 
rated population (data not shown). Second, CD5 + human 
B cells purified from cord blood were tested for their ability 
to secrete  hlbl0 either spontaneously or after activation under 
conditions resulting in the production of high Ig levels, such 
as SAC plus IL-2 or the combination of SAC with the CD40 
system (20). As shown in Fig. 2, CD5 + B lymphocytes did 
not constitutively secrete hlL-10. Stimulated  CD5 + B cells 
were able to produce low levels of hlL-10. The secretion was 
observed after 12 h and the peak was reached after 48 h of 
culture. Otherwise, resting or activated chronic lymphocytic 
leukemia CD5 + B cells from five different patients tested did 
not secrete IL-10 (data not shown). Thus, in contrast to the 
results generated in the murine system (22, 32), the CD5 + 
B lymphocytes subpopulation  did not appear to constitute 
the main source of  hilt0 production within the whole human 
B cell population. 
Taken together, these results indicate that activated normal 
human B lymphocytes are able to secrete significant levels 
of hlL-10, but did not reach those obtained for human B cell 
lines. 
Normal Human B Lymphocytes  Secrete  High Amounts of  hll_,lO 
after EBV Infection.  Since most of the EBV-positive B cell 
lines have the ability to produce hl'blO, we wondered whether 
EBV infection of normal B lymphocytes  would induce them 
to secrete II.-10 levels higher than those observed in response 
to the polyclonal activators. Thus, tonsillar purified B cells 
were infected by EBV and cultured for 30 d. At different time 
points, culture supernatants were harvested and tested in the 
IL-10 ELISAs and viable cell recovery was determined using 
trypan blue dye exclusion. For the experiment illustrated in 
Fig. 3, medium changes, indicated by arrows, were performed 
when B cell concentration reached saturation at "~,3 x  106 
ceUs/ml. During the first 6 d after EBV infection, when strong 
cell death occurred, no significant amount of Ibl0 could be 
detected in culture supernatants.  However, an induction of 
hlbl0 production was observed in supernatants 6 d after the 
culture onset, when the number of initially seeded cells was 
recovered. Thereafter, hlL-10 concentrations increased up to 
9 ng/ml at day 14, when all the B lymphocytes acquired the 
typical morphology of  immortalized lymphoblastoid cells and 
expressed Epstein-Barr nuclear antigens  as detected by im- 
munofluorescence (data not shown). At later time points, 
cells continued to grow with a high proliferation rate, while 
the hlL-10  level slowly decreased down to ml ng/ml, where 
it remained stable for >6 wk (data not shown).  The EBV 
infection of  purified tonsillar B cells isolated from 12 different 
donors led to the same results with on average 6.6  +  1.8 
ng/ml of hlL-10 detected at the peak, obtained between days 
14 and 19. Interestingly,  no vlL-10 could be detected at any 
time  of the kinetics.  Thus,  EBV  transformation induces 
purified B lymphocytes to secrete high amounts of hlIA0. 
Addition of Exogenous IL.IO Potentiates  EBV-induced  B Cell 
Proliferation." To examine further the role of hlL-10 during 
EBV infection of  normal B cells, the effect  of  exogenous hll.-10 
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Figure 3.  hlbl0 production during EBV transformation  of purified 
human B cells. Tonsillar purified B lymphocytes were infected by EBV 
as described in Materials and Methods  and then cultured at  5  x  105 
cells/ml.  Supematants  were harvested at different time points and then 
assayed in the IL-10  ELISAs. Viable cell recovery (f-l) was determined by 
trypan blue dye exclusion at different time points after EBV infection. 
Cell culna'es were split at one fourth at the time points indicated by arrows. 
EBV transformation  of purified B lymphocytes induced hlL-10 secretion 
(0),  No vi1r  induction was detected at any time of the kinetic. 
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Figure 4.  Exogenous hll.-10 potentiates  proliferation of EBV-infected 
B lymphocytes. EBV-infected tonsillar B lymphocytes were cultured at 
5  x  105 cells/ml without (m) or with (B) hlL-10 (100 ng/ml), added 
only at day 0. During the 24 d after infection, the cell number was deter- 
mined  using trypan blue dye exclusion. Identical medium changes occurred 
for both conditions (with or without hll_,10) at the same time points. on cell growth was tested. Purified rhlL-10 was added at day 
0,  immediately after purified B lymphocytes had been in- 
cubated  2 h with EBV. The number of viable B cells was 
determined at different time points over a 20-d kinetic. Results 
shown in Fig. 4 are expressed as cumulative theoretical cell 
numbers. The addition of exogenous hlL-10 accelerated the 
recovery of the viable cell number initially seeded (day 4 with 
exogenous hll.-10 vs. day 6 for the control medium). This 
enhancement of cell proliferation was quite potent between 
days 7 and 16, when addition of exogenous hlL-10 induced 
a twofold increase of viable B cells. Thereafter, the effect of 
exogenous hll~10 became less pronounced. This potentiating 
effect of exogenous hlL-10 was observed on five independent 
experiments  performed with purified B cells isolated from 
different donors. These results suggested that hlL-10 was a 
proliferation factor for EBV-infected B cells. Therefore, the 
endogenous secretion of hlL-10 observed during EBV infec- 
tion of  purified B lyrnphocytes could be involved in the mech- 
anisms sustaining cell proliferation and leading to the estab- 
lishment of the cell line. 
Anti-IL IO-neutralizing Antiserum Inhibits EBV-induced  B Cell 
Proliferation.  To further study the role of  endogenously pro- 
duced hIL-10 in the proliferation of EBV-infected  B cells, we 
generated neutralizing polyclonal  anti-IL,10 antibodies. Rabbits 
were immunized with highly purified rhIL-10 as described 
in Materials and Methods.  The antisera obtained  after five 
injections  were tested  for their ability  to  antagonize  the 
blocking effect of purified rhIL-10 on the IFN-3' production 
by activated spleen mononuclear cells. As shown in Fig. 5, 
the anti-IL-10 antiserum, diluted at 1:100, completely blocked 
the effect of 10 ng/ml of hIL-10 and antagonized 80% of the 
effect of 100 ng/ml, while the preimmune control serum re- 
mained inactive. 
So as to block endogenous hIbl0, the neutralizing or con- 
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Figure 5.  The rabbit polyclonal anti-lie10 antiserum neutralizes the effect 
of pure hlL-10 in a CSIF assay. Spleen mononuclear  cells were activated 
as described in Materials and Methods.  The initial  IFN-3, level (0) was 
dose-~lependeutly inhibited by addition of increasing concentrations of pure 
hll..10 (,).  The anti-IL-10 (['7) or control (O) antisera diluted  at  1:100 
were  assayed for their ability  to neutralize  this  inhibitory effect. 
trol antisera, diluted at 1:100, were added at the onset of the 
culture, immediately after EBV infection of  B cells and there- 
after every 5 d. The viable cell recovery was determined for 
each culture condition at different time points of the kinetic. 
Fig. 6 illustrates the results obtained for one of three inde- 
pendent experiments leading to the same following observa- 
tions. The addition of  anti-Ibl0 antiserum delayed  the recovery 
of the initial cell number and strongly reduced the cell prolifer- 
ation over the 22-d culture. At day 17, the number of viable 
cells cultured with anti-II.-10 antiserum was fivefold lower 
than  that  of cells cultured with control antiserum or in 
medium alone. During the same period,  the control serum 
remained inactive. Experiments,  where increasing dilutions 
(1:100, 1:500, 1:1,000, 1:5,000) of the anti-II.-10 and control 
antisera were added to infected B cells, were also performed. 
As illustrated in Fig. 7 A, the inhibition of cell growth was 
dose dependent and already observed  with a dilution of 1:1,000 
of  the anti-II.-10 antiserum. Whatever the dilutions, the control 
antiserum remained inactive. Moreover, Fig. 7 A  also illus- 
trates that addition of 250 ng/ml of exogenous hlI.-10 to the 
1:100 dilution  of the  neutralizing  antiserum  completely 
reversed its inhibitory effect and even resulted in the potenti- 
ation of B cell growth described above. 
To determine when the anti-IL-10 antiserum preferentially 
inhibited cell growth during the 22-d kinetic shown in Fig. 
6,  proliferation  rates, obtained  without or with anti-IL-10 
or control antisera, were calculated for two intervals: between 
days 0 and 17,  and between days 17 and 22.  As illustrated 
in Fig. 7 B, the inhibition of the proliferation rate mediated 
by the neutralizing anti-II.-10 antiserum reached 80% during 
the first time interval, whereas the proliferation  rates were 
identical after 17 d.  Moreover, when studied  after  10 wk, 
the cell lines established either with medium alone, control 
antiserum, or anti-IL-10 antiserum grew with approximately 
the same proliferation rate (data not shown). This indicates 
Figure 6.  A blocking polyclonal anti-II.-10 antiserum  strongly reduces 
proliferation  of EBV-transformed B cells. EBV-infected tonsiUar B lym- 
phocytes  were cultured at 5  x  10s cells/ml without (ll) or with anti- 
IL-10 antiserum  (k~) or control serum (J) diluted at 1:100. The number 
of viable cells was determined  on a 22-d kinetic by trypan blue dye exclu- 
sion. Medium changes were performed at the same time points for each 
culture condition. Cells were reseeded at  2.5  x  10  s cells/ml. 
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dose dependent  and reversible but does not prevent establishment  of the 
cell line. EBV-infected tonsillar B lymphocytes  were cultured at 5  x  10  s 
calls/m1 without (ll) or with anti-II:10 antiserum  ([~) or control serum 
(~1). (A) A dose-dependent  experiment  was performed with different di- 
lutions of the anti-IL-10  antiserum and control serum (1:100, 1:500, 1:1,000, 
1:5,000), and the reversibility of this effect was tested by addition of exog- 
enous hlbl0 (250 ng/ml) combined with the sera at 1:100. (B) The prolifer- 
ation index (which represented  the ratio of the proliferation  rate of the 
condition anti-Ibl0 or control antiserum  over the proliferation  rate  of 
the condition medium alone) was determined  for two time intervals  of 
the experiment  illustrated  in Fig. 6: between days 0 and 17, and between 
days 17 and 22. Results  are expressed as percentage  of control medium. 
that the anti-IL-10 antiserum delays but does not prevent the 
establishment of EBV-transformed B  cell lines. 
Discussion 
The screening of >40 B cell lines suggests that the secre- 
tion of II.-10 is associated with the mature and preplasmo- 
cytic stages of B cell development, since none of the pro-B, 
pre-B,  or myeloma cell lines tested were able to produce IL- 
10.  The data also indicate an association between the pres- 
ence of the EBV genome and the secretion of hlir  since 
24 of 31 EBV-positive mature B cell lines secrete ID10, whereas 
only one of five EBV-negative mature B cell lines did so. It 
now remains to establish whether viral proteins such as EBNA 
2-6 or latent membrane protein may be involved in the trans- 
activation of the hlL-10 gene, as it has already been shown 
for several B cell activation markers such as CD23 or Bac-1 
(33). Nonetheless, a few EBV-positive B cell lines do not pro- 
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duce hlL-10, and two EBV-negative B cell lines were able to 
secrete hlL-10 (BJAB and IARC 518).  BJAB may produce 
hlL-10 as a consequence of an intricate pattern of chromo- 
somic translocations,  different from the classical translocations 
that exist in other Burkitt lymphomas (34). The mechanisms 
leading to the production of hlL-10 by the preplasmocytic 
cell line IARC 518 also remain to be elucidated. This strong 
association between EBV expression and hlbl0 production 
by a human B cell line is consistent with the results recently 
obtained with human B cell lines derived from patients with 
AIDS and Burkitt lymphoma (35). 
It is important to emphasize that vlL-10 was only seldomly 
detected and, if so, at low levels. In fact, vlL-10 has been de- 
scribed as being expressed only during the late phase of the 
virus lyric cycle (36).  Thus, the occasional detection of only 
low amounts of vlL-10 in the supernatants of lymphoblastoid 
cell lines is consistent with the fact that EBV is present in 
these cells in  a latent  state.  It will be of interest to check 
whether the cell lines producing vlL-10 are also able to pro- 
duce the virus. Finally, the fact that EBV induces the expres- 
sion of a cellular gene (hlL-10), with a viral counterpart (vlL-10) 
already existing within the viral genome, still remains an un- 
resolved issue. 
The present  study also  indicates that  the production of 
hlL-10 by human B cells is not restricted to cell lines since 
normal B lymphocytes can also  secrete hlbl0  after activa- 
tion. These results are consistent with the detection by PCR 
of the hlL-10 mRNA for some EBV-transformed B cell lines 
and also for SAC-activated normal human B lymphocytes (18). 
However, whatever the B cell origin (tonsils, spleen, periph- 
eral blood, or cord blood) and the polyclonal activator used, 
the maximum of hlL-10 production was low (0.35 ng/ml for 
106 cells initially seeded).  In fact, these levels are comparable 
to those described for mouse B cells (22).  None of the tested 
B  cell subpopulations  (tonsil  IgD +  or IgD-,  cord blood 
CD5 +) was found to produce higher levels of hlL-10.  This 
is in apparent contrast to results obtained with mouse B cells, 
where II.-10 production appears  to be associated  with CD5 
expression (32). 
The biological meaning of such a level of Ibl0 secretion 
remains difficult to establish as concentrations of hlL-10 <0.5 
ng/ml do not affect B cell growth or differentiation (19). Thus, 
this endogenous production of hlL-10 by B cells does not 
seem to be sufficient to induce autocrine B cell proliferation 
or differentiation. This is consistent with the strong B cell 
progression activity of  exogenous IL-10  observed in the CD40 
system (19,  20).  In this context, we were particularly sur- 
prised by the low hlbl0 levels observed in response to the 
combination of the CD40 system and SAC, conditions that 
represent a thymoindependent  B cell activation pathway, where 
large amounts of Igs are secreted (20). Indeed, we had hypothe- 
sized that the important Ig production observed under these 
culture conditions was the consequence of a high production 
of endogenous hlL-10.  However, an autocrine loop,  occur- 
ring without release of Ibl0 outside cells, might happen then. 
In our hands, EBV was the sole agent able to induce normal 
human B lymphocytes to secrete high levels of IL-10. Indeed, 
after EBV transformation of purified normal B cells, a notice- able production of hi1:10 was observed, whereas no vlbl0 
induction was detectable. The bib10 secretion was well cor- 
related with the growth of infected cells. The peak of  produc- 
tion extended from day 12 to 18, a critical stage for establish- 
ment of the cell line.  Moreover, two findings indicate that 
this production of hi1:10 plays a facilitating role in the estab- 
lishment of the transformed cell line. First, addition of exog- 
enous hi1:10 at the onset of the culture resulted in an earlier 
and stronger proliferation of the transformed cells. Second, 
the addition of a blocking polyclonal anti-I1:10  antiserum 
efficiently slowed down cell growth. However, the neutralizing 
antiserum did not prevent the transformation of B lympho- 
cytes and the establishment of the cell line. This is consistent 
with the results obtained with antiviral cytokines as powerful 
as IFN-c~ or IFN-% which delay but do not prevent the es- 
tablishment of EBV-transformed cell lines (37, 38). Taken to- 
gether, these results suggest that the endogenous hlbl0 secre- 
tion is closely associated to the EBV-induced B cell proliferation 
during the early stages of cell transformation. Once estab- 
lished, the cell line apparently becomes independent of hlbl0 
since exogenous bib10  or anti-Ibl0  antibody turn out to 
be inefficient at this stage. In this context, several cytokines 
have already been proposed as autocrine growth factors for 
long-term established human lymphoblastoid cell lines: .I1:5 
(39), II:6 (8), adult T cell leukemia--derived factor/thioredoxin 
(40),  TNF-/~ (9), or soluble CD23  (10).  We are presently 
trying to determine whether hi1:10 plays an autocrine role 
in the proliferation of Burkitt lymphoma B cell lines and 
normal B lymphocytes. This may be difficult to establish since 
the growth of B cells is likely to depend on the coordinated 
action of several redundant growth factors. 
Since secretion of hI1:10 appears in vitro to be related to 
the proliferation of EBV-infected B lymphocytes, it is tempting 
to speculate that this cytokine may be involved in vivo in 
EBV-associated  B cell lymphoproliferative disorders. These 
include infectious mononucleosis and EBV-associated B cell 
lymphomas of immunocompromised subjects.  Studies are 
presently under way to determine whether patients suffering 
from such diseases exhibit abnormal levels of hi1:10 within 
the tumoral area or in their biological fluids.  In addition, 
this endogenous production of hi1:10 by EBV-transformed 
B lymphocytes may also be involved in an immunosuppres- 
sire process in response to the viral infection through two 
different mechanisms: by inhibiting the production of IFN-% 
a potent antiviral cytokine (38) produced by T cells and NK 
ceils (14), and by inhibiting antigen presentation to T cells 
(41). Thus, EBV may induce the secretion of Ibl0 by B lym- 
phocytes to protect itself from the immune reaction subse- 
quent to viral infection. In this context, we recently found 
that simultaneous addition of EBV and Ibl0 on total PBMC 
from EBV-positive  donors suppresses  reactivation of EBV- 
specific cytotoxicity and permits establishment of lympho- 
blastoid cell lines (Burdin, N., and F. Rousset, unpublished 
observations). Taken together, these results suggest that the 
Ibl0 production by EBV-transformed B cells may also repre- 
sent an evasion mechanism against the host antiviral systems. 
Therefore, the EBV-induced production of hlbl0 may play 
a dual role: (a) by suppressing the antiviral arms of the im- 
mune system, and (b) by enhancing the survival and the growth 
of their hosts,  the B lymphocytes. 
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